Time-dependent endpoints as predictors of overall survival in multiple myeloma

• Published in: BMC cancer Vol. 13; no. 1; p. 122
• Main Authors: Félix, Jorge, Aragão, Filipa, Almeida, João M, Calado, Frederico J, Ferreira, Diana, Parreira, António B S, Rodrigues, Ricardo, Rijo, João F R
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16-03-2013; BioMed Central
• Subjects: Aged; Analysis; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Care and treatment; Clinical trials; Disease-Free Survival; Economic models; Estimates; FDA approval; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Medical research; Medicine, Experimental; Middle Aged; Multiple myeloma; Multiple Myeloma - mortality; Multiple Myeloma - therapy; Prognosis; Randomized Controlled Trials as Topic; Statistical methods; Studies; Transplantation, Homologous; Variables; United States > US
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-13-122

Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients.
Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman's rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model.
We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7-3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate.
TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation.